Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine)

International Journal of Antimicrobial Agents

Volumn 22, Issue 4, 2003, Pages 380-387

  Seifert, Karin ^a   Matu, Sangeeta ^a   Pérez Victoria, F Javier ^b   Castanys, Santiago ^b   Gamarro, Francisco ^b   Croft, Simon L ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Drug resistance; Hexadecylphosphocholine; Leishmania; Miltefosine

Indexed keywords

ANTIPROTOZOAL AGENT; EDELFOSINE; GLYCOPROTEIN P; MILTEFOSINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; CULTURE MEDIUM; GENE AMPLIFICATION; IN VITRO STUDY; LEISHMANIA DONOVANI; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; WILD TYPE;

EID: 0141457689     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00125-0     Document Type: Article

References (42)

1. Murray H.W. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int. J. Infect. Dis. 4:2000;158-177.
2. Croft S.L., Yardley V. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8:2002;319-342.
3. Eibl H., Unger C. Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat. Rev. 17:1990;233-242.
4. Brachwitz H., Vollgraf C. Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharm. Ther. 66:1995;39-82.
5. Sundar S., Makharia A., More D.K., et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin. Infect. Dis. 31:2000;1110-1113.
6. Jha T.K., Sundar S., Thakur C.P., et al. Miltefosine, an oral agent, for the treatment of Indian visceral Leishmaniasis. New Engl. J. Med. 341:1999;1795-1800.
7. Soto J., Toledo J., Gutierrez P., et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 33:2001;57-61.
8. Croft S.L., Neal R.A., Pendergast W., Chan J.H. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. 36:1987;2633-2636.
9. Croft S.L., Snowdon D., Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. 38:1996;1041-1047.
10. Kuhlencord A., Maniera T., Eibl H., Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. 36:1992;1630-1634.
11. 3 (edelfosine) and amphotericin B. Acta Trop. 81:2002;151-157.
12. Wieder T., Reutter W., Orfanos C.E., Geilen C.C. Mechanism of action of phospholipid analogs as anticancer compounds. Prog. Lipid Res. 38:1999;249-259.
13. Rybczynska M., Spitaler M., Knebel N.G., Boeck G., Grunicke H., Hofmann J. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem. Pharmacol. 62:2001;765-772.
14. Lira R., Contreras L.M., Santa-Rita R.M., Urbina J.A. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J. Antimicrob. Chemother. 47:2001;537-546.
15. Lux H., Heise N., Klenner T., Hart D., Opperdoes F.R. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol. 111:2000;1-14.
16. Santa-Rita R.M., Santos Barbosa H.S., Meirelles M.N.S.L., de Castro S.L. Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop. 75:2000;219-228.
17. Perez-Victoria J.M., Perez-Victoria F.J., Parodi-Talice A., et al. Alkyl-lysophospholipid resistance in multidrug resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob. Agents Chemother. 45:2001;2468-2474.
18. Tovar J., Cunningham M.L., Smith A.C., Croft S.L., Fairlamb A.H. Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: effect on parasite intracellular survival. Proc. Natl. Acad. Sci. 95:1998;5311-5316.
19. ®. Parasitol. Int. 48:2000;265-269.
20. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning - A Laboratory Manual. 2nd ed:1989;Cold Spring Harbor Laboratory Press, Plainview, New York.
21. Chiquero M.J., Perez-Victoria J.M., O'Valle F., et al. Altered drug membrane permeability in a multidrug-resistant Leishmania tropica line. Biochem. Pharmacol. 55:1998;131-139.
22. Chu G., Vollrath D., Davis R.W. Separation of large DNA molecules by contour-clamped homogeneous electric field. Science. 234:1986;1582-1585.
23. Arana F.E., Perez-Victoria J.M., Repetto Y., Morello A., Castanys S., Gamarro F. Involvement of thiol metabolism in resistance to glucantime in Leishmania tropica. Biochem. Pharmacol. 56:1998;1201-1208.
24. Mbongo N., Loiseau P.M., Billion M.A., Roberto-Gero M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 42:1998;352-357.
25. Haimeur A., Oulette M. Gene amplification in Leishmania tarentolae selected for resistance to sodium stibogluconate. Antimicrob. Agents Chemother. 42:1998;1689-1694.
26. Achterberg V., Gercken G. Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 23:1987;117-122.
27. Berkovic D., Haase D., Hiddemann W., Fleer E.A. Induction of resistance in the human leukaemia cell line HL60 towards hexadecylphosphocholine and other ether phospholipids analogues. J. Exp. Ther. Oncol. 6:1996;368-375.
28. Achterberg V., Gercken G. Metabolism of ether lysophospholipids in Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 26:1987;277-287.
29. Zoeller R.A., Layne M.D., Modest E.J. Animal cell mutants unable to take up biologically active glycerophospholipids. J. Lipid Res. 36:1995;1866-1875.
30. Fleer E.A., Berkovic D., Grunwald U., Hiddemann W. Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB. Eur. J. Cancer. 32:1996;506-511.
31. Rybczynska M., Liu R., Lu P., et al. MDR1 causes resistance to the antitumour drug miltefosine. Br. J. Cancer. 84:2001;1405-1411.
32. Fu D., Shi Z., Wang Y. Bcl-2 plays a key role instead of mdr1 in the resistance to hexadecylphosphocholine in the human epidermoid tumor cell line KB. Cancer Lett. 142:1999;147-153.
33. Diomede L., Salmona M., Lamorte G., Piovani B., Sozzani S. Protein kinase C is not involved in cholesterol-induced resistance to synthetic ether lipids. Anticancer Res. 13:1993;1331-1334.
34. Grondin K., Kundig C., Roy G., Ouellette M. Linear amplicons as precursors of amplified circles in methotrexate-resistant Leishmania tarentolae. Nucleic Acids Res. 26:1998;3372-3378.
35. Olmo A., Arrebola R., Bernier V., Gonzalez-Pacanowska D., Ruiz-Perez L.M. Co-existence of circular and multiple linear amplicons in methotrexate-resistant Leishmania. Nucleic Acids Res. 23:1995;2856-2864.
36. Detke S., Chaudhuri G., Kink J.A., Chang K.P. DNA amplification in tunicamycin-resistant Leishmania mexicana. Multicopies of a single 63-kilobase supercoiled molecule and their expression. J. Biol. Chem. 263:1988;3418-3424.
37. Ouellette M., Haimeur A., Grondin K., Legare D., Papadopoulou B. Amplification of ABC transporter gene pgpA and of other heavy metal resistance genes in Leishmania tarentolae and their study by gene transfection and gene disruption. Methods Enzymol. 292:1998;182-193.
38. Ouellette M., Borst P. Drug resistance and P-glycoprotein gene amplification in the protozoan parasite Leishmania. Res. Microbiol. 142:1991;737-746.
39. Henderson D.M., Sifri C.D., Rodgers M., Wirth D.F., Hendrickson N., Ullman B. Multidrug resistance in Leishmania donovani is conferred by amplification of a gene homologous to the mammalian mdr1 gene. Mol. Cell Biol. 12:1992;2855-2865.
40. Gueiros-Filho F.J., Viola J.P., Gomes F.C., et al. Leishmania amazonensis: multidrug resistance in vinblastine-resistant promastigotes is associated with rhodamine 123 efflux, DNA amplification, and RNA overexpression of a Leishmania mdr1 gene. Exp. Parasitol. 81:1995;480-490.
41. Unger C., Fleer E., Damenz W., Hilgard P., Nagel G., Eibl H. Hexadecylphosphocholine: determination of serum concentrations in rats. J. Lipid Mediators. 3:1991;71-78.
42. Ganguly N.K. Oral miltefosine may revolutionize treatment of visceral leishmaniasis. The potential impact of miltefosine on visceral leishmaniasis in India. TDR News. 68:2002;2.